To advance the models used and to compensate the shortcomings of available models, novel AD models are under pipeline including oAβ25-35 model, transgenic model expressing 82-kDa ChAT, oDGal mouse and APP knock-in rat. This evidence concerns the gene APP and Alzheimer disease.